The latest clinical outcomes from the largest and longest follow-up to the Diabetes Prevention Program study will be presented at 8:00 a.m. CT. The current phase of the Diabetes Prevention Program Outcomes Study is scheduled to run through 2021 and is examining the long-term effects of metformin on cardiovascular disease and cancer outcomes, according to DPPOS Chair David M. Nathan, MD.
Coming up: Latest DPPOS results on CVD, cancer incidence to be reported
